Novel glucokinase activators: A patent review (2008 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 1, 2011, Pages 13-33

  Sarabu, Ramakanth ^a   Berthel, Steven J ^a   Kester, Robert F ^a   Tilley, Jefferson W ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Amino acid based GKA; Aromatic ring centered GKA; AZD 1656; Glucokinase activator; MK0941; TTP 399

Indexed keywords

4 (CYCLOPROPYL SULFONYL)PHENYL OXALIC AMIDE; 5 TRIFLUOROMETHYL 2 PYIDONE; BENZENE DERIVATIVE; GLUCOKINASE; GLUCOKINASE ACTIVATOR; IMIDAZOLE DERIVATIVE; PYRIDINE; UNCLASSIFIED DRUG;

CHIRALITY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; GLUCOSE HOMEOSTASIS; GLUCOSE UTILIZATION; HUMAN; HYDROGEN BOND; INSULIN RELEASE; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG INDUSTRY; ENZYME ACTIVATION; GLUCOKINASE; HUMANS; HYPOGLYCEMIC AGENTS; PATENTS AS TOPIC;

EID: 78650501835     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.542413     Document Type: Review

References (43)

1. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301:370-3
2. Sarabu R, Berthel SJ, Kester RF, Tilley JW. Glucokinase activators as new type 2 diabetic therapeutic agents. Expert Opin Ther Pat 2008;18:759-68
3. Fyfe MCT, Procter MJ. Glucokinase activators as potential antidiabetic agents possessing superior glucose lowering efficacy. Drugs Future 2009;34:641-53
4. Matschinsky F. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8:399-417
5. Matschinsky F, Magnuson MA, editors. Glucokinase and glycemic disease. S. Karger AG, Basel; 2004
6. Pfizer, Inc., USA. Fluorinated heteroaryls. WO2010013161; 2010
7. Pfizer, Inc., USA. Substitured heteroaryls. US2010063063; 2010
8. Pfefferkorn JA, Lou J, Minich ML, et al. Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle. Bioorg Med Chem Lett 2009;19:3247-52
9. Takeda Pharmaceutical Co. Ltd, Japan; Takeda San Diego, Inc. Glucokinase activators. WO2008079787; 2008
10. Takeda Pharmaceutical Co. Ltd, Japan; Takeda San Diego, Inc. Glucokinase activators. WO2009140624; 2009
11. Takeda Pharmaceutical Co. Ltd, Japan; Takeda San Diego, Inc. Glucokinase activators. WO2008116107; 2008
12. F. Hoffmann-La Roche AG, Switz. Pyrrolidinone glucokinase activators. WO2009127546; 2009
13. F. Hoffmann-La Roche AG, Switz. Pyridazinone glucokinase activators. WO2009127544; 2009
14. Tanabe Seiyaku Co., Ltd., Japan. Hydrazones. JP20100037337; 2010
15. Sidduri A, Grimsby JS, Corbett WL, et al. 2,3-Disubstituted acrylamides as potent glucokinase activators. Bioorg Med Chem Lett 2010;20:5673-76
16. AstraZeneca AB, Sed.; AstraZeneca UK Ltd. Therapeutic agents 414. WO2010015849; 2010
17. Advinus Therapeutics Private Ltd, India. 2,2,2-Trisubstituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application. WO2008104994; 2008
18. Advinus Therapeutics Private Ltd, India. Acetamide derivatives as glucokinase activators, their process and pharmaceutical application. WO2009047798; 2009
19. Merck GmbH, Germany. beta-Aminoacids for treatment of diabetes. WO2009092432; 2009
20. Takeda Pharmaceutical Co. Ltd, Japan. Nitrogen containing five membered heterocyclic compound. WO2008136428; 2008
21. Takeda Pharmaceutical Co. Ltd, Japan. Nitrogenated 5-membered heterocyclic compound. WO2009128481; 2009
22. AstraZeneca AB, Sed.; AstraZeneca UK Ltd. Benzoyl heterocyclyl compounds as glucokinase (GLK) activators. WO200805117; 2008
23. AstraZeneca AB, Swed.; AstraZeneca UK Ltd. Chemical compounds. WO2008050101; 2008
24. AstraZeneca AB, Swed.; AstraZeneca UK Ltd. Chemical compounds. WO20100092387; 2010
25. AstraZeneca AB, Swed.; AstraZeneca UK Ltd. Chemical compounds. WO20100092386; 2010
26. Banyu Pharmaceutical Co. Ltd, Japan. Method for producing pyrazol-3-yl-benzamide derivative. WO2009041475; 2009
27. Merck GmbH, Germany. N-(Pyrazol-3-yl)-benzamide derivatives as glucokinase activators. WO2009046802; 2009
28. Novo Nordisk A/S, Denmark. Benzamide glucokinase activators. WO2007125105; 2007
29. Merck GmbH, Germany. Pyridine derivatives useful as glucokinase activators. WO2009046784; 2009
30. Merck GmbH, Germany. Carboxamide-heteroaryl derivatives for the treatment of diabetes. WO2009106209; 2009
31. Banyu Pharmaceutical Co. Ltd, Japan. 2-Pyridine carboxamide derivative having GK-activating activity. WO2008044777; 2008
32. Merck GmbH, Germany. 5-Oxo-2,3,4,5-tetrahydro-benzo[b] oxapine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxapine-4-carboxylic acid amide for treatment and prevention of diabetes type 1 and type 2. WO2009109270; 2009
33. Novo Nordisk A/S, Denmark. Urea glucokinase activators. WO2008084043; 2008
34. Novo Nordisk A/S, Denmark. Urea glucokinase activators. WO2008084044; 2008
35. Takeda Pharmaceutical Co. Ltd, Japan; a) Fused ring compounds and use thereof. WO2009125873; 2009. b) Indole compound. US2008096877; 2008
36. Takeda Pharmaceutical Co. Ltd, Japan. Fused heterocyclic compound. WO2008047821; 2008
37. Banyu Pharmaceutical Co. Ltd, Japan. Fused heterocyclic compound. WO2009063821; 2008
38. Bristol-Myers Squibb Co., USA. Novel glucokinase activators methods of using same. WO2008005914; 2008
39. Bristol-Myers Squibb Co., USA; a) 1,3-Dihyrdroxy substituted phenylamide glucokinase activators. WO200815463; 2008. b) Novel glucokinase activators and methods of using same. WO2008005964; 2008
40. Leighton B, Atkinson A, Coghlan MP. Small molecule glucokinase activators as novel anti-diabetic agents. Biochemical Soc Trans 2005;33:371-4
41. Novo Nordisk A/S, Denmark. Use of liver selective glucoskinase activators. US20080026987, 2008. Available from: www.clinicaltrials.gov
42. Tilley JW. Glucokinase activators: Novo Nordisk's WO2008084044 and Array Biopharma's WO2008091770. Expert Opin Ther Pat 2009;19:549-53
43. NovoNordsk Press Release which may be Accessed from: http://www.ttpharma. com/PressReleases/2007/20070220TransTechPharmaInc/tabid/195/Default.aspx